215 related articles for article (PubMed ID: 19445901)
1. A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells.
Kang MR; Kang JS; Han SB; Kim JH; Kim DM; Lee K; Lee CW; Lee KH; Lee CH; Han G; Kang JS; Kim HM; Park SK
Biochem Pharmacol; 2009 Sep; 78(5):486-94. PubMed ID: 19445901
[TBL] [Abstract][Full Text] [Related]
2. KBH-A42, a histone deacetylase inhibitor, inhibits the growth of doxorubicin-resistant leukemia cells expressing P-glycoprotein.
Kang MR; Lee K; Kang JS; Lee CW; Lee KH; Kim JH; Yang JW; Kim BG; Han G; Kang JS; Park SK; Kim HM
Oncol Rep; 2010 Mar; 23(3):801-9. PubMed ID: 20127023
[TBL] [Abstract][Full Text] [Related]
3. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells.
Ahn MY; Jung JH; Na YJ; Kim HS
Gynecol Oncol; 2008 Jan; 108(1):27-33. PubMed ID: 17920664
[TBL] [Abstract][Full Text] [Related]
4. Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice.
Joung KE; Min KN; An JY; Kim DK; Kong G; Sheen YY
Cancer Res; 2006 May; 66(10):5394-402. PubMed ID: 16707467
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
6. A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells.
Takai N; Ueda T; Nishida M; Nasu K; Narahara H
Int J Mol Med; 2006 Feb; 17(2):323-9. PubMed ID: 16391833
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
Hsi LC; Xi X; Lotan R; Shureiqi I; Lippman SM
Cancer Res; 2004 Dec; 64(23):8778-81. PubMed ID: 15574791
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
9. Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis.
Wetzel M; Premkumar DR; Arnold B; Pollack IF
J Neurosurg; 2005 Dec; 103(6 Suppl):549-56. PubMed ID: 16383255
[TBL] [Abstract][Full Text] [Related]
10. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
Hwang JJ; Kim YS; Kim MJ; Jang S; Lee JH; Choi J; Ro S; Hyun YL; Lee JS; Kim CS
Anticancer Drugs; 2009 Oct; 20(9):815-21. PubMed ID: 19644355
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S
Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020
[TBL] [Abstract][Full Text] [Related]
12. Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A.
Seo JS; Cho NY; Kim HR; Tsurumi T; Jang YS; Lee WK; Lee SK
Oncol Rep; 2008 Jan; 19(1):93-8. PubMed ID: 18097580
[TBL] [Abstract][Full Text] [Related]
13. Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
Zopf S; Neureiter D; Bouralexis S; Abt T; Glaser KB; Okamoto K; Ganslmayer M; Hahn EG; Herold C; Ocker M
Int J Oncol; 2007 Dec; 31(6):1391-402. PubMed ID: 17982666
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
Baradari V; Huether A; Höpfner M; Schuppan D; Scherübl H
Endocr Relat Cancer; 2006 Dec; 13(4):1237-50. PubMed ID: 17158768
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
Sakajiri S; Kumagai T; Kawamata N; Saitoh T; Said JW; Koeffler HP
Exp Hematol; 2005 Jan; 33(1):53-61. PubMed ID: 15661398
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ
Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008
[TBL] [Abstract][Full Text] [Related]
17. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
18. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells.
Lee KW; Kim JH; Park JH; Kim HP; Song SH; Kim SG; Kim TY; Jong HS; Jung KH; Im SA; Kim TY; Kim NK; Bang YJ
Anticancer Res; 2006; 26(5A):3429-38. PubMed ID: 17094463
[TBL] [Abstract][Full Text] [Related]
20. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis.
Takai N; Kawamata N; Gui D; Said JW; Miyakawa I; Koeffler HP
Cancer; 2004 Dec; 101(12):2760-70. PubMed ID: 15536623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]